{"pub_date": "2016-01-06T00:00:00Z", "subsection_name": null, "lead_paragraph": "The insulin, called Afrezza, has had poor sales since being approved by the F.D.A. in 2014. Shares in its maker, MannKind, fell 48 percent.", "print_page": "2", "document_type": "article", "byline": {"person": [{"rank": 1, "organization": "", "lastname": "POLLACK", "firstname": "Andrew", "role": "reported"}], "original": "By ANDREW POLLACK"}, "multimedia": [{"width": 190, "height": 126, "url": "images/2016/01/06/business/06Insulin/06Insulin-thumbWide.jpg", "subtype": "wide", "legacy": {"wide": "images/2016/01/06/business/06Insulin/06Insulin-thumbWide.jpg", "widewidth": "190", "wideheight": "126"}, "type": "image"}, {"width": 600, "height": 400, "url": "images/2016/01/06/business/06Insulin/06Insulin-articleLarge.jpg", "subtype": "xlarge", "legacy": {"xlargewidth": "600", "xlargeheight": "400", "xlarge": "images/2016/01/06/business/06Insulin/06Insulin-articleLarge.jpg"}, "type": "image"}, {"width": 75, "height": 75, "url": "images/2016/01/06/business/06Insulin/06Insulin-thumbStandard-v2.jpg", "subtype": "thumbnail", "legacy": {"thumbnail": "images/2016/01/06/business/06Insulin/06Insulin-thumbStandard-v2.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "type": "image"}], "section_name": "Business Day", "headline": {"print_headline": "Shares of Inhaled Insulin Maker Plummet 48% as Big Marketing Partner Pulls Out", "main": "Sanofi Ends Marketing Deal With Developer of Inhaled Insulin"}, "source": "The New York Times", "blog": [], "word_count": "914", "web_url": "http://www.nytimes.com/2016/01/06/business/sanofi-ends-marketing-deal-with-developer-of-inhaled-insulin.html", "slideshow_credits": null, "news_desk": "Business", "type_of_material": "News", "snippet": "The insulin, called Afrezza, has had poor sales since being approved by the F.D.A. in 2014. Shares in its maker, MannKind, fell 48 percent.", "_id": "568c05fb38f0d803f4a0c464", "abstract": "Insulin developer MannKind announces that Sanofi is ending agreement in which it had rights to market inhaled insulin called Afrezza; drug has not met sales expectations since Food and Drug Administration approval.", "keywords": [{"rank": "1", "name": "organizations", "value": "Sanofi SA", "is_major": "Y"}, {"rank": "2", "name": "organizations", "value": "MannKind Corporation", "is_major": "Y"}, {"rank": "3", "name": "persons", "value": "Mann, Alfred E", "is_major": "N"}, {"rank": "4", "name": "organizations", "value": "Pfizer Inc", "is_major": "N"}, {"rank": "5", "name": "organizations", "value": "Food and Drug Administration", "is_major": "N"}, {"rank": "6", "name": "subject", "value": "Diabetes", "is_major": "N"}]}